News
Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a ...
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy ...
The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side ...
The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's popular weight-loss drug Wegovy ...
By triggering weight loss using the likes of Ozempic, people can expect various possible changes to their appearance ...
Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...
FDA seizes hundreds of fake Ozempic units from US supply after Novo Nordisk alerts regulators to counterfeit semaglutide ...
The European Medicines Agency has indicated that Novo Nordisk's drugs, Ozempic and Wegovy, may rarely cause a serious eye ...
3d
Zacks.com on MSNIs Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.
This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran ...
The European Medicines Agency said an eye condition that might cause loss of vision is a very rare side effect of Novo Nordisk's blockbuster drugs Ozempic and Wegovy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results